The antiobesity drug Orlistat induces cytotoxic effects, suppresses Her-2/neu (erbB-2) oncogene overexpression, and synergistically interacts with trastuzumab (Herceptin) in chemoresistant ovarian cancer cells.
Menendez
J A
JA
Department of Medicine, Breast Cancer Translational Research Program, Evanston Northwestern Healthcare Research Institute, Evanston, IL 60201, USA. jmenendez@enh.org
Vellon
L
L
Lupu
R
R
D019440:Anti-Obesity Agents / Q000494:pharmacology*; D000911:Antibodies, Monoclonal / Q000494:pharmacology*; D061067:Antibodies, Monoclonal, Humanized; D002277:Carcinoma / Q000188:drug therapy / Q000235:genetics; D045744:Cell Line, Tumor / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D005260:Female; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects*; D018734:Genes, erbB-2 / Q000187:drug effects*; D006801:Humans; D007783:Lactones / Q000494:pharmacology*; D000077403:Orlistat; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000235:genetics; D012680:Sensitivity and Specificity; D000068878:Trastuzumab
D019440:Anti-Obesity Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007783:Lactones; D000077403:Orlistat; D000068878:Trastuzumab